Clinical trial
Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease
NCT00349752 · UCB Pharma, Industry · Terminated
Key facts
| NCT number | NCT00349752 |
|---|---|
| Title | Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease |
| Official title | A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease. |
| Acronym | COSPAR1 |
| Lead sponsor | UCB Pharma, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Biological, Other |
| Interventions | certolizumab pegol 400 mg, Placebo |
| Enrollment | 174 |
| Start date | Nov 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Jul 10, 2006 |
| Last update posted | Aug 9, 2018 |
| Countries | Canada, Germany, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: